These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 27057683

  • 1. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R, Lee D, Leonard MB, Thayu M, Denson LA, Chuang E, Herskovitz R, Kerbowski T, Baldassano RN.
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S.
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF.
    Clinics (Sao Paulo); 2019 Apr 08; 74():e824. PubMed ID: 30994711
    [Abstract] [Full Text] [Related]

  • 9. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 08; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A, Straathof JW, Derijks LJ.
    Eur J Gastroenterol Hepatol; 2015 Mar 08; 27(3):242-8. PubMed ID: 25569569
    [Abstract] [Full Text] [Related]

  • 12. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B, Iborra M, Sáez-González E, Marqués-Miñana MR, Moret I, Cerrillo E, Tortosa L, Bastida G, Hinojosa J, Poveda-Andrés JL, Nos P.
    Dig Dis; 2019 Mar 08; 37(2):108-115. PubMed ID: 30149385
    [Abstract] [Full Text] [Related]

  • 13. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.
    Scand J Gastroenterol; 2017 Oct 08; 52(10):1086-1092. PubMed ID: 28622097
    [Abstract] [Full Text] [Related]

  • 14. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L, Kolho KL.
    J Pediatr Gastroenterol Nutr; 2017 Feb 08; 64(2):272-278. PubMed ID: 27149256
    [Abstract] [Full Text] [Related]

  • 15. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
    Teixeira FV, Sassaki LY, Saad-Hossne R, Baima JP, Magro DO, Coy CSR, Kotze PG.
    Arq Gastroenterol; 2018 Feb 08; 55(2):192-197. PubMed ID: 30043873
    [Abstract] [Full Text] [Related]

  • 16. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
    Levartovsky A, Ungar B, Yavzori M, Picard O, Fudim E, Eliakim R, Paul S, Roblin X, Ben-Horin S, Kopylov U.
    Int J Colorectal Dis; 2020 Jun 08; 35(6):1141-1148. PubMed ID: 32296932
    [Abstract] [Full Text] [Related]

  • 17. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
    Vahabnezhad E, Rabizadeh S, Dubinsky MC.
    Inflamm Bowel Dis; 2014 Apr 08; 20(4):606-13. PubMed ID: 24552827
    [Abstract] [Full Text] [Related]

  • 18. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S.
    Inflamm Bowel Dis; 2017 Jan 08; 23(1):126-132. PubMed ID: 28002129
    [Abstract] [Full Text] [Related]

  • 19. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.
    Inflamm Bowel Dis; 2013 Jan 08; 19(4):761-6. PubMed ID: 23446337
    [Abstract] [Full Text] [Related]

  • 20. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.
    Am J Gastroenterol; 2013 Jun 08; 108(6):962-71. PubMed ID: 23419382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.